Date: 2017-09-27
Type of
information: Initiation of development program
phase:
Announcement: initiation of development program
Company: Diamyd Medical (Sweden)
Product: Remygen® (gamma-Aminobutyric acid)
Action
mechanism:
- neurotransmitter. Remygen® is a patent-pending GABA (gamma-Aminobutyric acid)-based study drug with specific release and pharmacokinetic characteristics manufactured under GMP. GABA, the active substance in Remygen®, has been shown in clinical trials in healthy volunteers to enhance insulin secretion, and several preclinical studies support its effects on regenerating insulin producing beta cells, reducing inflammation and enhancing the effect of antigen-specific immunotherapy.
Disease:
Therapeutic
area:
Country:
Trial
details:
Latest
news:
- • On September 27, 2017, Diamyd Medical provided an update on the strategic development of the study drug Remygen®. The company has filed a preliminary patent application on the formulation and release characteristics of the GABA-based study drug Remygen®. Based on the feedback from a scientific meeting with the Swedish Medical Products Agency, and in collaboration with Diamyd Medical’s scientific network, the company will now commence designing the first clinical trial based on Remygen® and defining the long-term drug development strategy.
Is
general: Yes
